Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)
Harmony Biosciences Holdings (HRMY) reported Finished Goods of $2.8 million for Q4 2024, up 21.11% on a YoY basis from $2.3 million in Q1 2024, and down 17.04% sequentially from $3.3 million in Q3 2024.
Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 2 years of Finished Goods data on file, last reported at $2.8 million in Q4 2024.
- For the quarter ending Q4 2024, Finished Goods rose 21.11% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2024 stood at $2.8 million (up 21.11% YoY), and the FY2024 full-year result was $2.8 million, up 21.11% from the prior year.
- Finished Goods fell to $2.8 million in Q4 2024, from $3.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $3.3 million in Q3 2024 to a low of $2.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 2.28 Mn |